Discovery of BRM-123
Objective: To identify bioactive compounds with anticancer properties.
Method: Conducted marine bioprospecting in deep-sea environments to collect sponge samples. Using high-performance liquid chromatography (HPLC) and mass spectrometry (MS), we isolated BRM-123, a compound showing potent activity against breast and pancreatic cancer cells in preclinical trials.
Outcome: BRM-123 is currently in the preclinical development stage, with promising results indicating its potential as a novel cancer therapy.
Marine Algae and Antimicrobial Agents
Objective: To combat drug-resistant bacterial infections.
Method: Collected samples of marine algae from various coastal regions. Through bioassay-guided fractionation and advanced spectroscopic analysis, we identified MA-456, a compound with significant efficacy against multiple drug-resistant bacterial strains.
Outcome: MA-456 has shown exceptional promise in preclinical studies and has been patented for its unique antimicrobial properties.
Collaboration with Harvard University and Scripps Institution of Oceanography
Objective: To explore the therapeutic potential of marine biodiversity.
Method: Partnered with leading academic institutions to conduct joint research on marine-derived compounds. This collaboration has facilitated access to cutting-edge research facilities and advanced analytical techniques, enhancing our compound isolation and characterization processes.
Outcome: Several promising compounds have been identified, with ongoing studies aimed at understanding their mechanisms of action and therapeutic potential.